Nine patients (33%) were classified as MEITL, 11 (41%) as ATLL, and seven (26%) as other (one EBV+ CD56+; three EBV+ CD56 negative TNKCL; two indolent TLPD; one anaplastic large cell lymphoma (ALCL)). This evidence concerns the gene NCAM1 and adult T-cell leukemia/lymphoma.